Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells and the second most common type of leukemia in children and adults.
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an often fatal form of brain cancer, according to researchers at The University of Texas MD Anderson Cancer Center.
Melanoma patients’ response to a major form of immunotherapy is associated with the diversity and makeup of trillions of potential allies and enemies found in the digestive tract, researchers at The University of Texas MD Anderson Cancer Center report at the ASCO-Society for Immunotherapy in Cancer meeting in Orlando.
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance therapy (HMT) may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
Women with early-stage breast cancer who had an intermediate risk recurrence score (RS) from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study from The University of Texas MD Anderson Cancer finds.
Recognizing a critical need to address disparities in cancer care, The University of Texas MD Anderson Cancer Center has been designated as an ECHO superhub for oncology by the ECHO Institute at the University of New Mexico Health Science Center (UNMHSC). MD Anderson is one of just nine ECHO superhub sites in the world and the first focused on oncology.
A team from The University of Texas MD Anderson Cancer Center describes this week in the journal Nature a series of preclinical experiments using patient-derived tumor xenografts (PDXs) and mouse models that point to potential treatments for patients with a rapidly-progressing and resistant subgroup of tumor cells.
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
The University of Texas MD Anderson Cancer Center returns to Southern California this month with its Making Cancer History® Seminar, 3:30-5:30 p.m. Feb. 20 at the Renaissance Indian Wells Resort and Spa, 44400 Indian Wells Lane.
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which located a genetic site for the most common form of prostate cancer, has potential for developing precision therapy for other cancers, such as breast, brain and colorectal, say researchers at The University of Texas MD Anderson Cancer Center. Study results were published in the Feb. 6 online issue of Nature.
In honor of World Cancer Day on Feb. 4, The University of Texas MD Anderson Cancer Center calls for health care providers, organizations, governments and individuals to unite in the common goal of eliminating cancer. Driven to accelerate progress toward Making Cancer History®, MD Anderson is proud to support this global effort.
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment.
Charles Aubrey “Mickey” LeMaistre, M.D., past president of The University of Texas MD Anderson Cancer Center and a pioneering crusader against the harmful effects of tobacco use and catalyst of the field of cancer prevention, died today in Houston. He was 92. LeMaistre came to MD Anderson as president in 1978 after serving seven years as chancellor of The University of Texas System.
Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers.
Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, has been formed by The University of Texas MD Anderson Cancer Center, Deerfield Management and two leading autophagy experts.
As national vaccination rates for the human papillomavirus (HPV) remain low, The University of Texas MD Anderson Cancer Center has again united with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement endorsing the recently revised vaccination recommendations from the Centers for Disease Control and Prevention (CDC).
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center and Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced an exclusive strategic clinical development and commercialization collaboration to evaluate Affimed’s TandAb technology in combination with MD Anderson’s natural killer cell (NK) product.
In the first study evaluating patient-reported cosmetic outcomes in a population-based cohort of older women with breast cancer, The University of Texas MD Anderson Cancer Center researchers found that less radiation was associated with improved cosmetic satisfaction long-term.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right